New hope for aggressive breast cancer: targeted combo before surgery

This study tests whether adding the drug panitumumab to standard chemotherapy helps shrink tumors more effectively in people with a rare and aggressive type of breast cancer called triple-negative inflammatory breast cancer. About 42 participants will receive chemotherapy before surgery, with or without panitumumab, to see which approach leads to better outcomes. The goal is to reduce tumor size and limit the amount of breast tissue that needs to be removed.